Caffeine

Caffeine

Caffeine works primarily by blocking the molecule that tells your brain you’re tired (adenosine). This single mechanism drives most of what you feel — alertness, better performance, mood boost. Caffeine also inhibits phosphodiesterase at higher concentrations (increasing cyclic AMP) and affects intracellular calcium mobilisation, but adenosine receptor blockade is the dominant pathway at typical doses.

Caffeine does not create energy. It masks fatigue signals. The tiredness doesn’t disappear — it piles up until the caffeine wears off, which is why you eventually crash.

---

Key takeaways

• Caffeine doesn’t create energy — it blocks the signal that tells your brain you’re tired
• How fast you clear caffeine is genetic — half-life ranges from 1.5 to 9 hours, and most people don’t know their type
• Performance dose is 3–6 mg/kg taken 30–60 min before exercise
• Cut caffeine ≥9h before bed for coffee; ≥13h for high-dose pre-workout — even when sleep “feels fine”
• Tolerance develops in 1–2 weeks; full reset requires 7–12 days of abstinence
• Nonusers get ~28% endurance boost vs ~19% for habitual users — cycling off may restore full benefit
• Up to 400 mg/day is not associated with adverse effects in healthy adults; pregnancy limit is ≤200 mg/day
• Withdrawal is a validated syndrome — headache, fatigue, depressed mood — onset 12–24h, peaks 20–51h
• Coffee ≠ caffeine: decaf coffee shows similar mortality (−14%), T2D, and liver benefits as regular coffee — the coffee matrix, not caffeine, drives those associations
• Decaf at 2–3 cups/day is associated with reduced all-cause mortality and CVD risk (UK Biobank, 449k participants) — choose Swiss Water or CO₂ process over methylene chloride
• Filtered coffee avoids cholesterol-raising diterpenes while preserving beneficial polyphenols; brew method matters
• For exercise and cognitive performance, caffeine from any source works; for long-term metabolic associations, coffee itself appears to matter
• Coffee is associated with reduced osteoporosis risk (2025 meta-analysis, OR 0.79) — the old “bad for bones” claim is overturned when calcium intake is adequate
• Combined L-theanine + caffeine suggests focused attention benefits beyond caffeine alone — but evidence is largely industry-funded
• Moderate coffee (3–6 cups/day) does not dehydrate habitual consumers

---

For supplement and product reviews, see klatiCHECK.

---

How caffeine works

Adenosine is a chemical that builds up in your brain while you’re awake. As it accumulates, it binds to receptors that make you feel sleepy and slow your neurons down.

Caffeine fits into those same receptors but doesn’t activate them. While caffeine is sitting in the receptor, adenosine can’t signal — so you feel alert. Once the caffeine is broken down, all the accumulated adenosine rushes in at once. This is why caffeine late in the day wrecks sleep — the tiredness doesn’t disappear, it just gets delayed into your sleep window.

---

How fast you clear caffeine — it’s genetic

Caffeine half-life averages 5 hours in healthy adults but varies from 1.5 to 9 hours depending on a single gene (CYP1A2). This determines whether you’re a fast or slow metaboliser.

• Fast metabolisers: Clear caffeine quickly. Can handle afternoon doses without sleep problems. Pre-workout caffeine benefits are reliable.
• Slow metabolisers: Caffeine lingers for hours. Afternoon caffeine measurably degrades sleep quality even when it still “feels fine.” Heart risk may increase at high intakes in this group.

You can’t tell your type from how you feel alone — many slow metabolisers get used to the alertness effect while still losing deep sleep. A genetic test is the only reliable way to know.

---

Dose and timing

Context	Dose	Timing
Ergogenic (exercise)	3–6 mg/kg body weight	30–60 min pre-exercise
Daily alertness	100–200 mg	Morning only
Sleep-protective cutoff	—	8–10h before bed
Tolerance reset	0 mg	7–12 days full abstinence

Higher doses (>6 mg/kg) do not further improve performance and increase side effects (anxiety, GI distress, tachycardia). The dose-response curve for ergogenic benefit plateaus around 3–6 mg/kg across most populations studied.

Habitual consumers develop adenosine receptor upregulation — more receptors are created to compensate for chronic blockade. This is tolerance. It develops within 1–2 weeks and requires 7–12 days of complete abstinence to reverse.

---

Physical performance

Caffeine improves both endurance and strength performance across a wide range of exercise types. The ergogenic window is 3–6 mg/kg taken 30–60 min before exercise in healthy adults.

Endurance: A meta-analysis of 46 studies found caffeine improves mean power output by approximately 2–4% in time-trial performance. The effect is consistent across cycling, running, and rowing.

Strength and power: A separate meta-analysis of 10 studies found significant improvements in maximal muscle strength and muscular endurance at caffeine doses of 3–9 mg/kg. Effects are most reliable for compound movements (squat, bench press) and less consistent for isolated muscle groups.

These benefits are acute — they depend on the dose consumed before each session. Chronic use builds tolerance to the alertness effect but the ergogenic effect on physical output appears more resistant to tolerance, though evidence on this point is still limited.

---

Cognitive performance

Caffeine improves attention accuracy during exercise in healthy adults. A systematic review and meta-analysis of 13 randomised cross-over studies found significant benefits for attention but not for reaction time or inhibitory control. Improvements in self-reported energy and mood were consistent across studies.

The strongest cognitive evidence is in sleep-deprived individuals. A meta-analysis of 45 studies found caffeine restores response time, executive function, and information processing accuracy to near-baseline levels following sleep loss. In the rested state, cognitive gains are smaller and more variable.

Mechanism: caffeine blocks adenosine-mediated inhibition of excitatory neurotransmitters (dopamine, noradrenaline), which explains improvements in sustained attention and processing speed. These are acute effects — tolerance development reduces the alertness benefit for habitual consumers.

---

Long-term associations

Observational data link habitual caffeine intake to reduced risk of several neurodegenerative conditions. These are epidemiological associations, not proven causal effects.

Parkinson’s disease: A meta-analysis of 13 cohort studies found that regular caffeine consumers had a 20% lower risk of Parkinson’s disease (HR = 0.80, 95% CI: 0.75–0.85) compared to non-consumers. The association is dose-dependent and specific to caffeine — not coffee alone — consistent with the adenosine A2A receptor mechanism in the basal ganglia.

Coffee and metabolic health: Large observational meta-analyses associate coffee consumption with lower risks of type 2 diabetes and liver cirrhosis. However, decaffeinated coffee shows similar protective effects in both cases, suggesting the benefits come from other coffee compounds (chlorogenic acids, diterpenes) rather than caffeine itself. These findings should not be attributed to caffeine supplementation.

---

Side effects

A comprehensive systematic review of >5000 articles found that up to 400 mg/day in healthy adults is not associated with overt adverse cardiovascular, behavioural, or acute effects. However, specific populations and dose thresholds carry meaningful risk.

Pregnancy

Caffeine during pregnancy is associated with dose-dependent increases in low birth weight risk. A meta-analysis of 13 prospective studies (90,747 participants) found that each 100 mg/day increment is associated with 13% higher risk of low birth weight (RR 1.13, 95% CI 1.06–1.21), with effects scaling from 50 mg/day upward. Current guidelines recommend limiting intake to ≤200 mg/day during pregnancy, though some researchers argue no safe threshold has been established.

Withdrawal

Caffeine withdrawal is a validated clinical syndrome supported by 57 experimental studies. Onset occurs 12–24 hours after abstinence, peaks at 20–51 hours, and lasts 2–9 days. Validated symptoms include headache (50% incidence), fatigue, decreased alertness, depressed mood, difficulty concentrating, and irritability. Clinically significant distress occurs in 13% of cases. Doses as low as 100 mg/day produce withdrawal symptoms upon cessation (older evidence).

Anxiety

Caffeine is anxiogenic in susceptible individuals, particularly those with panic disorder or specific ADORA2A gene variants. This is a dose-dependent pharmacological effect — not psychological — mediated through adenosine receptor subtypes that modulate GABAergic inhibition. Individuals with anxiety disorders should titrate carefully or avoid high doses.

Cardiovascular

A meta-analysis of interventional studies found no significant effect of caffeine on ventricular premature beats in humans (RR 1.00, 95% CI 0.94–1.06), though animal models showed reduced ventricular fibrillation threshold at very high doses not typical of human consumption. Moderate caffeine intake does not increase arrhythmia risk in healthy adults at typical doses.

---

Interactions

Caffeine competes with several nutrients and drugs:

• Sleep: Even when subjective sleep quality feels unchanged, caffeine consumed within 6 hours of sleep measurably reduces slow-wave (deep) sleep. See the sleep module for architecture details.
• Iron absorption: Polyphenols in coffee and tea (not caffeine itself) reduce non-heme iron absorption by up to 50–90% when consumed with meals. This applies to both caffeinated and decaffeinated coffee. Separate coffee/tea from iron-rich meals by 1–2 hours.
• Magnesium: Caffeine increases urinary magnesium excretion. Chronic high intake without supplementation may contribute to marginal deficiency. See klatiLYTE for electrolyte protocols.
• Calcium and bone: Caffeine modestly increases urinary calcium excretion. However, a 2025 meta-analysis of 14 studies (562,838 participants) found coffee consumption is associated with reduced osteoporosis risk (OR 0.79), and Mendelian randomisation confirmed a protective causal direction. The old concern appears relevant only at very high caffeine intakes combined with low calcium intake (<744 mg/day). With adequate calcium, coffee appears protective for bone health.
• Oral contraceptives and other CYP1A2 inhibitors: Oral contraceptives roughly double caffeine half-life. Fluvoxamine and ciprofloxacin have similar effects. Individuals on these medications should reduce caffeine intake or extend timing cutoffs.

---

Caffeine vs coffee

Not all caffeine effects come from caffeine. Disentangling what caffeine does from what coffee does is necessary for accurate recommendations.

Caffeine-driven effects

• Exercise performance: Pure caffeine capsules improve strength and endurance — coffee is not required.
• Cognitive acute effects: Caffeine from any source (pills, coffee, tea) restores attention and processing speed after sleep loss.
• Parkinson’s disease: The association is caffeine-specific. Decaffeinated coffee does not show the same protective association, consistent with adenosine A2A receptor mechanisms in the basal ganglia.

Coffee-driven effects (not attributable to caffeine)

• Type 2 diabetes: A meta-analysis of 18 studies (457,922 participants) found that each additional cup of coffee is associated with a 7% lower risk of T2D (RR 0.93, 95% CI 0.91–0.95). Critically, decaffeinated coffee shows similar protective associations (older evidence). A larger dose-response meta-analysis confirms this (older evidence). The benefit likely comes from chlorogenic acids and other non-caffeine compounds.
• Liver protection: Coffee consumption, including decaffeinated, is associated with reduced risk of cirrhosis and non-alcoholic fatty liver disease. A meta-analysis of 11 epidemiological studies found significant protective associations for both NAFLD and liver fibrosis.
• Cholesterol: Unfiltered coffee (French press, Turkish) contains diterpenes (cafestol, kahweol) that raise LDL cholesterol dose-dependently. In a randomised crossover study, cafestol raised total cholesterol by 0.79 mmol/L and LDL by 0.57 mmol/L at 60 mg/day (older evidence). Paper-filtered and instant coffee contain negligible diterpenes. Caffeine pills carry zero diterpene exposure.

Practical distinction

If you use caffeine for exercise performance or acute cognitive effects, pills or any caffeinated source works. For the long-term metabolic and hepatoprotective associations seen in epidemiological data, the coffee matrix — not caffeine alone — appears to drive the benefit. Brew method matters: filtered coffee avoids the LDL-raising diterpenes while preserving polyphenol content.

---

Coffee beyond caffeine

Coffee contains over 1000 bioactive compounds. The health associations attributed to “coffee” in epidemiological studies are driven by this matrix — not caffeine alone. Decaffeinated coffee retaining most of these compounds shows similar benefits for metabolic outcomes.

Chlorogenic acids

Chlorogenic acids (CGAs) are the dominant polyphenol class in coffee — 70–350 mg per cup depending on brew method. A meta-analysis of 5 RCTs (364 participants) found CGA supplementation reduces systolic blood pressure by 4.31 mmHg (95% CI −5.60 to −3.01) and diastolic by 3.68 mmHg. However, the included trials were confined to Asian populations and funded by CGA manufacturers — independent replication is needed.

CGAs also function as antioxidants and may modulate glucose metabolism, though human evidence for these endpoints remains limited (preliminary).

Diterpenes — cafestol and kahweol

Cafestol is the most potent dietary cholesterol-raising compound identified. It is present in coffee oil and retained in unfiltered brews (French press, Turkish, espresso to a lesser degree). Paper filtration removes >95% of diterpenes. In a randomised crossover trial, cafestol raised total cholesterol by 0.79 mmol/L and LDL by 0.57 mmol/L over 28 days in 10 male volunteers (older evidence).

Brew method	Diterpene content	LDL impact
French press	High	Raises LDL
Turkish/boiled	High	Raises LDL
Espresso	Moderate	Modest
Paper-filtered	Negligible	No effect
Instant	Negligible	No effect

Melanoidins

Melanoidins are Maillard reaction products formed during roasting — they constitute up to 25% of roasted coffee’s dry matter. They are associated with prebiotic activity, promoting beneficial gut bacteria, and antioxidant capacity. Dark roasts contain more melanoidins but fewer chlorogenic acids.

Gut effects

Coffee stimulates gastric acid secretion, promotes colonic motility (the “coffee makes you poop” effect), and its polyphenols and melanoidins may act as prebiotics supporting gut microbiota diversity. A literature review found that coffee modulates gut microbiota composition and promotes bowel function in healthy individuals. These effects involve both caffeine (motility) and non-caffeine compounds (prebiotic activity).

Roasting and brewing

• Light roast: Preserves the most chlorogenic acids (highest polyphenol content).
• Medium roast: Optimises total antioxidant capacity — balances CGAs and melanoidins.
• Dark roast: Melanoidin-rich but depleted in CGAs; phenolic compounds are incorporated into melanoidin structures.
• Brew method: Paper filtration removes diterpenes (protects LDL) while preserving polyphenols. French press retains diterpenes. Cold brew extracts fewer CGAs than hot brewing.

Acrylamide

Acrylamide is a process contaminant formed via the Maillard reaction during coffee roasting. IARC classifies it as a probable human carcinogen (Group 2A) based on animal data. However, epidemiological evidence does not support a cancer risk from dietary acrylamide at normal human exposure levels.

A dose-response meta-analysis of 16 epidemiological studies (1,151,189 participants, 48,175 cancer cases, median follow-up 14.9 years) found no association between the highest versus lowest dietary acrylamide exposure and any site-specific cancer, with no evidence of dose-response thresholds. A separate systematic review of 63 epidemiological studies reached the same conclusion.

Roast level and acrylamide: the relationship is nuanced and not fully resolved. Acrylamide forms early in roasting and partially degrades at higher temperatures. Most studies find that light-to-medium roasts contain the highest acrylamide levels — a review found peak concentrations of 730 µg/kg at light/medium roast in Arabica. However, individual studies report conflicting results: one found that dark roasting increased acrylamide content (303 vs 260 µg/kg for light), possibly confounded by storage-time differences, while another found that light roast had significantly lower acrylamide (93.7 µg/kg) than very dark roast roasted to 245°C. An Ames mutagenicity test found lighter roast coffee showed higher mutagenic potential that was reduced to control levels in dark roast, suggesting the overall carcinogenic burden may decrease with darker roasting.

Critically, brewed coffee contains only 5–80 µg/kg acrylamide — far below the levels in French fries (779–1299 µg/kg) or potato chips. Additionally, longer roasting that reduces acrylamide tends to increase other process contaminants (furan, furfuryl alcohol, 5-hydroxymethylfurfural), so there is no single “safest” roast level for all contaminants simultaneously.

Bottom line: at normal coffee consumption (3–6 cups/day), acrylamide exposure is not associated with increased cancer risk regardless of roast level. The roast-level variation in acrylamide content is a food chemistry nuance, not a health decision point.

---

Decaffeinated coffee

Decaf deserves its own section because the health evidence is surprisingly strong — and because the processing method matters.

Decaf health outcomes

A dose-response meta-analysis of 21 cohort studies (10.1 million participants, 240,303 deaths) found similar inverse associations with all-cause mortality for both caffeinated and decaffeinated coffee — 3 cups/day associated with 13% lower mortality risk (Li et al. 2019). The UK Biobank study (449,563 participants, 12.5 years) confirmed this: decaf at 2–3 cups/day was associated with 14% lower all-cause mortality (HR 0.86) and reduced cardiovascular disease risk (Chieng et al. 2022).

What decaf retains (coffee-matrix effects): metabolic protection (T2D risk reduction), liver protection (cirrhosis, NAFLD), mortality reduction, cardiovascular disease risk reduction, polyphenol and melanoidin content.

What decaf loses (caffeine-specific effects): ergogenic exercise benefit, acute cognitive enhancement, Parkinson’s disease protection, arrhythmia risk reduction (the UK Biobank study found only ground and instant — not decaf — reduced arrhythmia risk, consistent with caffeine’s adenosine A2A mechanism).

Who should choose decaf

• CYP1A2 slow metabolisers who want the coffee-matrix benefits without the prolonged caffeine exposure
• Pregnant women seeking to stay below the 200 mg/day threshold while still drinking coffee
• Individuals with anxiety disorders or caffeine sensitivity
• Afternoon/evening coffee drinkers who want to protect sleep architecture
• Anyone on CYP1A2 inhibitors (oral contraceptives, fluvoxamine, ciprofloxacin)

Decaffeination methods

Not all decaf is created equal. The method determines both residual caffeine content and chemical safety.

Method	Solvent	Caffeine removal	Notes
Swiss Water Process	None (water + carbon filtration)	99.9%	Chemical-free; preserves flavour; organic-compatible
CO₂ process	Supercritical CO₂	~97%	Selective for caffeine; preserves most compounds; used by large producers
Methylene chloride (direct)	Dichloromethane	~97%	IARC Group 2B (possibly carcinogenic); EPA banned for most consumer uses in 2024; FDA allows ≤10 ppm residue
Ethyl acetate	Ethyl acetate	~97%	Often marketed as “naturally decaffeinated” (ethyl acetate occurs in fruit); less flavour loss than MC

Residual caffeine: all decaf methods leave 2–15 mg per cup (vs ~95 mg for regular drip coffee). For most people this is negligible, but extreme caffeine-sensitive individuals should be aware.

Recommendation: prefer Swiss Water Process or CO₂-decaffeinated coffee when available. Avoid methylene chloride–processed decaf given regulatory concerns (EU limit is 2 ppm, stricter than FDA’s 10 ppm).

Caffeine vs regular coffee vs decaf — comparison

Health outcome	Caffeine (any source)	Regular coffee	Decaf coffee
Exercise performance	✓ Direct effect	✓ Via caffeine	✗ Minimal caffeine
Acute cognition / alertness	✓ Direct effect	✓ Via caffeine	✗ Minimal caffeine
Sleep disruption	✗ Dose-dependent harm	✗ Via caffeine	✓ Minimal impact
Parkinson’s risk reduction	✓ Caffeine-specific	✓ Via caffeine	✗ No association
Type 2 diabetes risk reduction	✗ Not caffeine	✓ Coffee matrix	✓ Similar benefit
Liver protection (cirrhosis, NAFLD)	✗ Not caffeine	✓ Coffee matrix	✓ Similar benefit
All-cause mortality reduction	? Unclear	✓ ~13% at 3 cups/day	✓ Similar benefit
Arrhythmia risk reduction	✓ Caffeine-mediated	✓ Via caffeine	✗ No association
Cholesterol (LDL) risk	—	✗ Unfiltered raises LDL	✗ Same diterpene issue
Anxiety risk	✗ Dose-dependent harm	✗ Via caffeine	✓ Minimal risk
Bone health	— Modest Ca²⁺ loss	✓ Net protective (OR 0.79)	✓ Similar (polyphenol-mediated)

---

Sleep architecture

Caffeine disrupts sleep even when taken hours before bed and even when subjective sleep quality feels normal.

A meta-analysis of 24 studies found that caffeine reduces total sleep time by 45 minutes and sleep efficiency by 7%, increases sleep onset latency by 9 minutes, and adds 12 minutes of wake after sleep onset. Deep sleep (N3/N4) duration decreases by 11.4 minutes and proportion by 1.4 percentage points, while light sleep (N1) increases. These effects are dose-dependent and time-dependent.

A randomised crossover trial found that 400 mg taken 6 hours before bed still reduced total sleep time by over 1 hour compared to placebo, with participants unable to detect the difference subjectively (older evidence). Self-reported sleep quality is unreliable for detecting caffeine-induced sleep disruption.

Practical cutoffs from the meta-analysis: to avoid reductions in total sleep time, coffee (~107 mg per 250 mL) should be consumed at least 8.8 hours before bed and higher-dose pre-workout supplements (~218 mg) at least 13.2 hours before bed.

---

Caffeine and hydration

The belief that caffeine causes dehydration is not supported by controlled evidence at moderate intakes in habitual consumers.

A counterbalanced crossover study in 50 habitual coffee drinkers (3–6 cups/day) found no significant differences in total body water, urine volume, urine specific gravity, urine osmolality, or any haematological hydration marker between 4 days of coffee consumption (4 mg/kg caffeine) and 4 days of water-matched intake (industry-funded) (older evidence). The authors concluded that coffee consumed in moderation by habitual users provides similar hydrating qualities to water.

An 11-day controlled trial in 59 men consuming 0, 3, or 6 mg/kg/day of caffeine found no evidence of hypohydration at any dose across body mass, urine osmolality, urine specific gravity, urine colour, 24-hour urine volume, serum osmolality, or haematocrit (older evidence).

Caffeine does have an acute mild diuretic effect — particularly at high doses (>6 mg/kg) or in non-habitual consumers — but at moderate habitual intakes, fluid balance is maintained because compensatory mechanisms counteract the short-term increase in urine output.

---

L-theanine + caffeine synergy

L-theanine is a non-proteinic amino acid found naturally in tea. When combined with caffeine, evidence suggests synergistic benefits for focused attention that neither compound achieves alone.

A meta-analysis of 11 randomised placebo-controlled studies found moderate effect sizes in favour of combined caffeine and L-theanine for alertness and attention-switching accuracy within the first 2 hours post-dose (industry-funded) (older evidence). The effect was more consistent for the combination than for either compound alone.

Individual RCTs support this: 50 mg caffeine + 100 mg L-theanine improved attention-switching speed and accuracy and reduced susceptibility to distracting information compared to 50 mg caffeine alone (industry-funded) (older evidence). Similarly, 40 mg caffeine + 97 mg L-theanine improved task-switching accuracy, increased alertness, and reduced tiredness compared to placebo (industry-funded) (older evidence).

The proposed mechanism: caffeine increases arousal via adenosine blockade while L-theanine promotes alpha-wave brain activity (relaxation without sedation), together producing focused calm alertness. However, individual RCTs are small (n=27–44), and the key studies were funded by tea industry stakeholders. Larger independent replication is needed before claiming definitive synergy.

Practical: common supplement stacks use ~100 mg L-theanine per ~100 mg caffeine. The studied doses were lower (40–50 mg caffeine), which may not match typical real-world use.

---

Caffeine cycling and tolerance

Habitual caffeine use reduces both the subjective alertness effect and the magnitude of the ergogenic benefit.

A randomised double-blind crossover trial found that 5 mg/kg caffeine improved exercise time to exhaustion at 80% VO₂max by 28% in nonusers (ingesting <50 mg/day) but only 19% in habitual users (ingesting ≥300 mg/day). The ergogenic effect lasted at least 6 hours in nonusers but only 3 hours in users, despite similar blood caffeine concentrations (older evidence).

This difference is consistent with adenosine receptor upregulation — chronic caffeine use causes the brain to produce more adenosine receptors, requiring higher caffeine concentrations to achieve the same degree of receptor blockade.

Practical cycling strategy

• Full washout: 7–12 days of complete caffeine abstinence substantially reverses tolerance, consistent with adenosine receptor downregulation timelines.
• Strategic use: Reserve caffeine for competition or key training sessions rather than daily consumption to maintain the ergogenic advantage.
• Withdrawal management: Headache, fatigue, and depressed mood peak at 20–51 hours after abstinence (older evidence). Tapering over 3–5 days reduces severity.

---

Caffeine and cortisol

Caffeine acutely stimulates cortisol secretion, but habitual use substantially blunts this response.

A double-blind crossover trial in 96 healthy adults found that after 5 days of caffeine abstinence, a caffeine challenge caused a robust increase in salivary cortisol across the day (p <.0001). However, 5 days of prior caffeine intake at 300 or 600 mg/day abolished the cortisol response to the morning dose. Afternoon doses still elevated cortisol modestly — overall, cortisol responses were reduced but not eliminated in habitual consumers (older evidence).

The mechanism involves the hypothalamic-pituitary-adrenocortical (HPA) axis: caffeine stimulates cortisol release via central catecholamine pathways. With repeated exposure, partial tolerance develops — but the axis remains responsive to additional doses later in the day.

Practical implications: for habitual consumers, the cortisol response to morning coffee is minimal and not clinically concerning. For individuals returning from a caffeine break or first-time users, the cortisol spike is acute and transient — not sustained elevation. Concerns about chronic cortisol elevation from moderate daily caffeine use are not supported by this evidence.

---

Caffeine content by source

Caffeine content varies widely by source and preparation. Knowing approximate values helps control dose and timing.

Source	Typical caffeine (mg)	Notes
Espresso (30 mL shot)	63	High concentration per mL
Drip/filter coffee (240 mL)	95	Most common daily source
Decaf coffee (240 mL)	2–15	Varies by decaf method; not zero
Cold brew (240 mL)	100–200	Long extraction; varies widely
Black tea (240 mL)	47	L-theanine also present
Green tea (240 mL)	28	Lower caffeine, higher L-theanine
Cola (355 mL)	34
Energy drink (250 mL)	80	Often paired with taurine, B-vitamins
Pre-workout supplement	150–300	Read labels; doses vary greatly
Caffeine pill	100–200	Pure anhydrous; precise dosing
Dark chocolate (28 g)	12	Theobromine also present

Values are approximate and vary by brand and preparation. For ergogenic dosing (3–6 mg/kg), an 80 kg person needs 240–480 mg — roughly 2.5–5 cups of drip coffee or 1–2 caffeine pills.

---

For supplement and product reviews, check klatiCHECK for klati approved sources.

---

Research